Laru-zova demonstrated a positive safety profile and early efficacy in improving low luminance visual acuity in patients with X-linked retinitis pigmentosa, according to a presentation at the FLORetina-ICOOR meeting.
“These data show promising early improvements in low luminance visual acuity (LLVA) and may suggest modification of the underlying disease pathology,” lead author Paolo E. Stanga, MD, of The Retina Clinic London, told Healio.
In the nonrandomized, open-label, multicenter phase 2 DAWN trial, seven previously treated participants with X-linked retinitis pigmentosa caused